SecBot SecBot
8-K ·Filed May 19, 2026

INM

InMed Pharmaceuticals Inc.
BEARISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001062993-26-002787
8-K material event: Items 1.01
Actionable Insight ▼ Bearish

Monitor for any Form 4 filings indicating Armistice has exercised the options. If/when exercise occurs, expect substantial selling pressure as the holder can sell shares at a profit. The low exercise price relative to market suggests imminent exercise.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.60
T+0 close · May 19, 2026 · via day close
Latest settled
−10.63%
T+60 · $1.43
Vs SPY
−16.92%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 19 $1.60entry
  2. T+1 · 6mo ago +0.63%α −0.41% · $1.61
  3. T+5 · 6mo ago +3.75%α +1.45% · $1.66
  4. T+20 · 5mo ago −6.88%α −7.86% · $1.49
  5. T+60 · 3mo ago −10.63%α −16.92% · $1.43

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

InMed Pharmaceuticals amended preferred investment options held by Armistice Capital, reducing the exercise price from $16.60 to $0.80. This drastically increases the likelihood of exercise, which would bring significant dilution to existing shareholders. The move signals financial distress at the micro-cap company.

Key Facts

  • Exercise price on 278,761 preferred investment option shares reduced from $16.60 to $0.80.
  • Amendment entered into on May 18, 2026 with Armistice Capital Master Fund Ltd.
  • Total potential dilution of up to 278,761 common shares if fully exercised.
  • No new cash raised through this amendment.
  • Company market cap is approximately $2M, making dilution material.

Financial Impact

Potential dilution of up to 278,761 shares or roughly doubling the current share count based on market cap.

dilutionshare_count

Risk Factors

  • Massive dilution to existing shareholders upon exercise.
  • Potential near-term stock price decline from overhang of exercisable shares.
  • Indication of financial distress and need for future capital.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001062993-26-002787
Exhibit: exhibit99-1.htm0001062993-26-002787
Document: form8k.htm0001062993-26-002787
Document: 0001062993-26-002787-index-headers.html0001062993-26-002787
Document: 0001062993-26-002787-index.html0001062993-26-002787
Document: 0001062993-26-002787.txt0001062993-26-002787

US Market Status

Market Closed · Opens in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 19, 2026